OncLive TV

Joseph Mikhael, MD, discusses unmet needs in triple-class refractory multiple myeloma.

Jonathan C. Trent, MD, PhD, discusses the potential role of immunotherapy in gastrointestinal stromal tumors.

Robert M. Dean, MD, discusses remaining challenges in diffuse large B-cell lymphoma.

Daniel W. Lin, MD, discusses the importance of biomarker research in prostate cancer.

Cathy Eng, MD, FACP, FASCO, discusses ​contraindications for oxaliplatin-based therapy in colorectal cancer.

Tanios S. Bekaii-Saab, MD, FACP, discusses improved sequencing strategies in hepatocellular carcinoma.

Alan P. Z. Skarbnik, MD, discusses treatment strategies for patients with mantle cell lymphoma.

Emily C. Ayers, MD, discusses recent developments in chronic lymphocytic leukemia.

Kirsten ​L. Greene, MD, MAS, FACS, discusse​s the future of personalized therapy in prostate cancer.

Yelena Y. Janjigian, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of biomarker testing in gastrointestinal cancers.

Cathy Eng, MD, FACP, FASCO, discusses the role of ​preventive screening in colorectal cancer.

Joshua Brody, MD, discusses the potential role for bispecific antibodies in mantle cell lymphoma.

Allison Winter, MD, discusses the utility of PI3K inhibitors in chronic lymphocytic leukemia.

Leslie M. Randall, MD, MAS, ​discusses the unmet need​s in platinum-resistant ovarian cancer.

Janakiraman Subramanian, MD, discusses the potential utility of dostarlimab in ​previously treated patients with non–small cell lung cancer.

Suresh S. Ramalingam, MD, FASCO, discusses limitations with immunotherapy in non–small cell lung cancer.

Farrukh Awan, MD, discusses the importance of risk stratification in chronic lymphocytic leukemia.

Firas El Chaer, MD, discusses the limitations of JAK inhibitors in myelofibrosis.

Michael J. Cavnar, MD, discusses the roles of chemotherapy and surgery in metastatic colorectal cancer.

The Institutional Perspectives in Cancer webinars assemble academic and community-based physicians and healthcare professionals across key disciplines, ranging from medical to surgical oncology.

Emily C. Ayers, MD, discusses unmet needs in chronic lymphocytic leukemia.

Gagandeep Brar, MD, discusses the rise of new treatment approaches in hepatocellular carcinoma.

Jia Ruan, MD, PhD, discusses the evolving armamentarium ​in mantle cell lymphoma.

R. Lor Randall, MD, FACS, discusses the evolution of orthopedic surgery in sarcoma.

Caitlin Costello, MD, discusses tailoring induction therapy for patients with standard-risk and high-risk multiple myeloma.

Cathy Eng, MD, FACP, FASCO, discusses the role of adjuvant chemotherapy in colorectal cancer.

Deepa Jagadeesh, MD, discusses unmet needs in aggressive and rare lymphoma subtypes.

Reema A. Patel, MD, discusses limitations with chemotherapy in pancreatic cancer.

Naomi B. Haas, MD, discusses the role of prostate-specific membrane antigen in prostate cancer.

Chung-Han Lee, MD, PhD, discusses the rationale for evaluating telaglenastat in renal cell carcinoma.